Psilocybin-facilitated Treatment for Cocaine Use

The primary purpose of this study is to evaluate the feasibility and estimate the efficacy of psilocybin-facilitated treatment for cocaine use. We also will monitor the impact of psilocybin-facilitated treatment on the use of other drugs and outcomes relevant to cocaine involvement (e.g., criminal involvement).

Topic Addiction
Compound Placebo Psilocybin
Country United States of America
Visit trial
Status Recruiting
Results Published
Start date 01 May 2015
End date 01 November 2022
Phase Phase II
Design Blinded
Type Interventional
Generation First
Participants 40
Sex All
Age 25- 99
Therapy No

Trial Details

MRI assessment is a unique aspect of this study. As a potential biological mechanism of psilocybin's effect includes changes in default mode network functional connectivity (Carhart-Harris et al., 2012), we will determine if psilocybin's therapeutic effects are mediated by such changes. Moreover, as Glx (a brain metabolite that reflects glutamate) abnormalities have been shown to play a role in cocaine addiction, we will determine if psilocybin impacts Glx in the anterior cingulate cortex and hippocampus.

Trial Number NCT02037126

Sponsors & Collaborators

University of Alabama
Researchers at the University of Alabama are investigating the potential use of psychedelics in a number of disorders.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.